Results 201 to 210 of about 22,711 (279)

Pharmacy‐Based Immunization Delivery: A Comprehensive History and Current Challenges

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, Volume 9, Issue 6, June 2026.
ABSTRACT Pharmacists and their teams have a long history of involvement with vaccines. This paper describes the contributions of pharmacy‐based immunization delivery in the United States from the 1800's to date. Early activities centered around storage and distribution of antitoxins and vaccines. From the 1950s through the early 1990s, pharmacists were
Jean‐Venable R. Goode, Mitchel C. Rothholz, Stephan L. Foster, Erica R. Brody, John D. Gräbenstein   +4 more
wiley   +1 more source

Advanced Sensing and Delivery Technologies for Nose-to-Brain Administration: From Nanocarriers to Sensor-Integrated Organ-on-Chips. [PDF]

Sensors (Basel)
Liu X, Chen R, Wu F, Yu B, Zhou G, Hu S, Zhang H, Wang P, Xu B, Zhuang L.   +9 more
europepmc   +1 more source

Engineered Pericyte‐Targeted Extracellular Vesicles Protect Against Hypoperfusion‐Induced Cognitive Impairment and Vascular Demyelination

Journal of Extracellular Vesicles, Volume 15, Issue 6, June 2026.
Schematic illustration on a therapeutic strategy wherein engineered extracellular vesicles (EVs) are delivered intranasally and specifically target pericytes. In a model of chronic cerebral hypoperfusion (BCAS), this targeted approach preserves cerebral blood flow, reinforces blood‐brain barrier (BBB) integrity, stabilizes the neurovascular unit (NVU),
Weiwei Shen, Weishi Liu, Min Guo, Tongyao You, Yingzhe Wang, Tiansiyu Wen, Suzhen Liang, Xiaodi Xie, Yanfeng Jiang, Qiang Dong, Jin‐Tai Yu, Mei Cui   +11 more
wiley   +1 more source

Intranasal Nano-Delivery Systems: Emerging Strategies for Central Nervous System Disease Therapeutics. [PDF]

Int J Nanomedicine
Gao T, Chu Q, Xing X, Liu Y, Fu S, Liu D.   +5 more
europepmc   +1 more source

Intranasal Delivery of Bacterial Extracellular Vesicles Enables RNA Cargo Entry Into the Brain

Journal of Extracellular Vesicles, Volume 15, Issue 6, June 2026.
ABSTRACT Extracellular vesicles (EVs) released by bacteria are potent mediators of host–microbe interactions. They modulate immune responses, deliver functional molecules and influence disease progression. However, whether bacterial EVs can access the brain and functionally affect host cells remains unclear.
Jae Yeong Ha, So‐Mi Kim, Song‐Yi Choi, Chanyong Park, Sungsu Park, Su‐Hyung Hong, Il‐Sung Jang, Youngkyun Lee, Heon‐Jin Lee   +8 more
wiley   +1 more source

Chitosan-Based Nanoparticles for Nose-to-Brain Drug Delivery: A Real Path toward Effective CNS Therapy? [PDF]

ACS Biomater Sci Eng
Riani LR, Seno GFB, Silva DM, Toledo CR, Paiva MRB, Santos JS, Fabri RL, Pittella F, Tavares GD.   +8 more
europepmc   +1 more source

Extracellular Vesicles of Giardia duodenalis: Unravelling Their Virulence Factors and Potential to Induce Protection Against Experimental Giardiasis

Journal of Extracellular Biology, Volume 5, Issue 6, June 2026.
ABSTRACT Extracellular vesicles (EVs) are key mediators of intercellular communication, enabling trans‐kingdom exchange of proteins, nucleic acids, lipids, and metabolites. In Giardia duodenalis, EVs contribute to parasite survival, host–pathogen interactions, and immune modulation.
Corral‐Ruiz Gerardo, Argüello‐García Raúl, Ortiz‐Lozano Dalia, Salazar‐Villatoro Lizbeth, Pech‐Santiago Edar Onam, Espinosa‐Cantellano Martha, Hernández‐Cueto Daniel, Silva‐Olivares D. Angélica, Betanzos Abigail, Ortega‐Pierres M. Guadalupe   +9 more
wiley   +1 more source

Overcoming the blood-brain barrier in Alzheimer's disease: translational perspectives on advanced drug delivery platforms. [PDF]

Front Neurosci
Roamcharern N, Yubolphan R.
europepmc   +1 more source

Phage Therapy as an Alternative Strategy Against Pseudomonas aeruginosa: A Narrative Review of Preclinical and Clinical Evidence

MicrobiologyOpen, Volume 15, Issue 3, June 2026.
Phage therapy shows promising efficacy against MDR, XDR, and PDR Pseudomonas aeruginosa infections across different models and administration routes. Evidence highlights reduced mortality, bacterial clearance, and synergy with antibiotics, while emphasizing the need for standardized protocols and advanced delivery systems to support clinical ...
Gustavo Aparecido da Cunha, Raine Piva Amaral, Ana Luisa Cauvila dos Santos, Bárbara Rafaela Ferreira Aio, Maria Fernanda Romboli Durante, Luiz Cosme Cotta Malaquias, Gabriel Magno de Freitas Almeida, Luiz Felipe Leomil Coelho   +7 more
wiley   +1 more source

Host–Pathogen Dual Targeting With Repurposed Drugs Identifies a Synergistic Therapy for Intracellular Staphylococcus aureus

MicrobiologyOpen, Volume 15, Issue 3, June 2026.
A large intracellular drug‐repurposing screen identifies a potent synergy between 5‐fluoro‐2′‐deoxycytidine and rifapentine, acting through dual host–pathogen targeting to reduce Staphylococcus aureus burdens across strains, cell types, and infection models (created with BioRender).
Blanca Lorente‐Torres, Helena Á. Ferrero, Pablo Castañera, Jesús Llano‐Verdeja, Sergio Fernández‐Martínez, Amanda Herrero‐González, Farzaneh Javadimarand, Roberto López, Jesús F. Aparicio, Andrew M. Edwards, Volker Behrends, Luis M. Mateos, Álvaro Mourenza, Michal Letek   +13 more
wiley   +1 more source